BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

630 related articles for article (PubMed ID: 28421406)

  • 21. Bone marrow 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography cannot replace bone marrow biopsy in diffuse large B-cell lymphoma.
    Adams HJ; Kwee TC; Fijnheer R; Dubois SV; Nievelstein RA; de Klerk JM
    Am J Hematol; 2014 Jul; 89(7):726-31. PubMed ID: 24711255
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Newly diagnosed lymphoma: initial results with whole-body T1-weighted, STIR, and diffusion-weighted MRI compared with 18F-FDG PET/CT.
    van Ufford HM; Kwee TC; Beek FJ; van Leeuwen MS; Takahara T; Fijnheer R; Nievelstein RA; de Klerk JM
    AJR Am J Roentgenol; 2011 Mar; 196(3):662-9. PubMed ID: 21343511
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison between whole-body MRI with diffusion-weighted imaging and PET/CT in staging newly diagnosed FDG-avid lymphomas.
    Albano D; Patti C; La Grutta L; Agnello F; Grassedonio E; Mulè A; Cannizzaro G; Ficola U; Lagalla R; Midiri M; Galia M
    Eur J Radiol; 2016 Feb; 85(2):313-8. PubMed ID: 26781135
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of F-18 FDG PET/CT in assessing bone marrow involvement in pediatric Hodgkin's lymphoma.
    Agrawal K; Mittal BR; Bansal D; Varma N; Srinivasan R; Trehan A; Manohar K; Kashyap R; Bhattacharya A; Marwaha RK
    Ann Nucl Med; 2013 Feb; 27(2):146-51. PubMed ID: 23143537
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Whole-body MRI for initial staging of paediatric lymphoma: prospective comparison to an FDG-PET/CT-based reference standard.
    Littooij AS; Kwee TC; Barber I; Granata C; Vermoolen MA; Enríquez G; Zsíros J; Soh SY; de Keizer B; Beek FJ; Hobbelink MG; Bierings MB; Stoker J; Nievelstein RA
    Eur Radiol; 2014 May; 24(5):1153-65. PubMed ID: 24563179
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Whole-body MRI for the detection of bone marrow involvement in lymphoma: prospective study in 116 patients and comparison with FDG-PET.
    Adams HJ; Kwee TC; Vermoolen MA; de Keizer B; de Klerk JM; Adam JA; Fijnheer R; Kersten MJ; Stoker J; Nievelstein RA
    Eur Radiol; 2013 Aug; 23(8):2271-8. PubMed ID: 23591618
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Preliminary evaluation of PET-CT and DWI for the detection of lymphoma bone marrow infiltration].
    Wu Y; Su LP; Yang XT; Zhang JX; Zhao M; Zhang Z; Guan T; Liu XL; Zheng YP; Han WE
    Zhonghua Zhong Liu Za Zhi; 2016 Nov; 38(11):853-860. PubMed ID: 27998446
    [No Abstract]   [Full Text] [Related]  

  • 28. Role of bone marrow biopsy in staging of patients with classical Hodgkin's lymphoma undergoing positron emission tomography/computed tomography.
    Puccini B; Nassi L; Minoia C; Volpetti S; Ciancia R; Riccomagno PC; Di Rocco A; Mulè A; Toldo C; Sassone MC; Guariglia R; Filì C; Finolezzi E; Falorio S; Zanon S; Furlan A; Doa G; Zaja F;
    Ann Hematol; 2017 Jul; 96(7):1147-1153. PubMed ID: 28451805
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Performance of Positron Emission Tomography-Computed Tomography and Bone Marrow Biopsy in Detecting Bone Marrow Infiltration in Lymphoma Cases.
    Büyükşimşek M; Kolsuz İ; Yetişir AE; Tohumcuoğlu M; Oğul A; Mirili C; Paydaş S; Güney İB
    Turk J Haematol; 2020 Nov; 37(4):220-225. PubMed ID: 32003552
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prospective comparison of 18-FDG PET/CT and whole-body diffusion-weighted MRI in the assessment of multiple myeloma.
    Mesguich C; Hulin C; Latrabe V; Lascaux A; Bordenave L; Hindié E; Marit G
    Ann Hematol; 2020 Dec; 99(12):2869-2880. PubMed ID: 32951093
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management.
    Pelosi E; Penna D; Deandreis D; Chiappella A; Skanjeti A; Vitolo U; Bisi G
    Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):9-16. PubMed ID: 18235420
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Utilization of 18F-FDG PET/CT as a staging tool in patients with newly diagnosed lymphoma.
    Cho SF; Chang CC; Liu YC; Chang CS; Hsiao HH; Liu TC; Huang CT; Lin SF
    Kaohsiung J Med Sci; 2015 Mar; 31(3):130-7. PubMed ID: 25744235
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis.
    Pakos EE; Fotopoulos AD; Ioannidis JP
    J Nucl Med; 2005 Jun; 46(6):958-63. PubMed ID: 15937306
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Whole-body MRI with diffusion-weighted sequence for staging of patients with suspected ovarian cancer: a clinical feasibility study in comparison to CT and FDG-PET/CT.
    Michielsen K; Vergote I; Op de Beeck K; Amant F; Leunen K; Moerman P; Deroose C; Souverijns G; Dymarkowski S; De Keyzer F; Vandecaveye V
    Eur Radiol; 2014 Apr; 24(4):889-901. PubMed ID: 24322510
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detection of bone marrow involvement in newly diagnosed post-transplant lymphoproliferative disorder: (18)F-fluorodeoxyglucose positron emission tomography/computed tomography versus bone marrow biopsy.
    Gheysens O; Thielemans S; Morscio J; Boeckx N; Goffin KE; Deroose CM; Sagaert X; Wlodarska I; Verhoef G; Dierickx D; Tousseyn T
    Leuk Lymphoma; 2016 Oct; 57(10):2382-8. PubMed ID: 26854937
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials.
    Kaddu-Mulindwa D; Altmann B; Held G; Angel S; Stilgenbauer S; Thurner L; Bewarder M; Schwier M; Pfreundschuh M; Löffler M; Menhart K; Grosse J; Ziepert M; Herrmann K; Dührsen U; Hüttmann A; Barbato F; Poeschel V; Hellwig D
    Eur J Nucl Med Mol Imaging; 2021 Oct; 48(11):3550-3559. PubMed ID: 33928400
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Whole-body diffusion-weighted imaging: the added value to whole-body MRI at initial diagnosis of lymphoma.
    Gu J; Chan T; Zhang J; Leung AY; Kwong YL; Khong PL
    AJR Am J Roentgenol; 2011 Sep; 197(3):W384-91. PubMed ID: 21862763
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exploring the role of FDG-PET in the assessment of bone marrow involvement in lymphoma patients as interpreted by qualitative and semiquantitative disease metabolic activity parameter.
    Kand PG; Tiwari BP; Basu S; Asopa RV; Nayak UN
    Indian J Cancer; 2010; 47(4):380-4. PubMed ID: 21131749
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow.
    Moog F; Bangerter M; Kotzerke J; Guhlmann A; Frickhofen N; Reske SN
    J Clin Oncol; 1998 Feb; 16(2):603-9. PubMed ID: 9469348
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Whole body MRI with Diffusion Weighted Imaging versus 18F-fluorodeoxyglucose-PET/CT in the staging of lymphomas.
    Maccioni F; Alfieri G; Assanto GM; Mattone M; Gentiloni Silveri G; Viola F; De Maio A; Frantellizzi V; Di Rocco A; De Vincentis G; Pulsoni A; Martelli M; Catalano C
    Radiol Med; 2023 May; 128(5):556-564. PubMed ID: 37145214
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.